Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
423.5 SEK | -1.40% |
|
-2.42% | +28.53% |
05-29 | Nordic Stocks Dropped Wednesday; NEL Fell Furthest | DJ |
04-24 | Nordic Shares Declined Wednesday; Svenska Handelsbnkn Ser A Fell Furthest | DJ |
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 163.67 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+28.53% | 1.27B | B | ||
-3.95% | 184B | C+ | ||
-0.90% | 109B | C | ||
-2.27% | 68.87B | A | ||
+15.24% | 46.61B | B- | ||
-6.00% | 46.39B | B- | ||
+5.36% | 40.74B | B+ | ||
+20.65% | 31.26B | B | ||
+11.60% | 24B | A- | ||
-5.50% | 24.24B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- XVIVO Stock
- Ratings Xvivo Perfusion AB